Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published January 2023 | Published + Supplemental Material
Journal Article Open

CRISPR mediated transactivation in the human disease vector Aedes aegypti

Abstract

As a major insect vector of multiple arboviruses, Aedes aegypti poses a significant global health and economic burden. A number of genetic engineering tools have been exploited to understand its biology with the goal of reducing its impact. For example, current tools have focused on knocking-down RNA transcripts, inducing loss-of-function mutations, or expressing exogenous DNA. However, methods for transactivating endogenous genes have not been developed. To fill this void, here we developed a CRISPR activation (CRISPRa) system in Ae. aegypti to transactivate target gene expression. Gene expression is activated through pairing a catalytically-inactive ('dead') Cas9 (dCas9) with a highly-active tripartite activator, VP64-p65-Rta (VPR) and synthetic guide RNA (sgRNA) complementary to a user defined target-gene promoter region. As a proof of concept, we demonstrate that engineered Ae. aegypti mosquitoes harboring a binary CRISPRa system can be used to effectively overexpress two developmental genes, even-skipped (eve) and hedgehog (hh), resulting in observable morphological phenotypes. We also used this system to overexpress the positive transcriptional regulator of the Toll immune pathway known as AaRel1, which resulted in a significant suppression of dengue virus serotype 2 (DENV2) titers in the mosquito. This system provides a versatile tool for research pathways not previously possible in Ae. aegypti, such as programmed overexpression of endogenous genes, and may aid in gene characterization studies and the development of innovative vector control tools.

Additional Information

© 2023 Bui et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. We thank Judy Ishikawa for mosquito husbandry assistance. We thank the Johns Hopkins Malaria Research Institute Insectary for providing the mosquito-rearing facility and the Parasitology Core facilities for providing the naïve human blood. The views, opinions, and/or findings expressed are those of the authors and should not be interpreted as representing the official views or policies of the U.S. government. This project has been funded in part by a DARPA Safe Genes Program Grant under contract number, HR0011-17-2-0047 and NIH awards, R01AI151004, DP2AI152071, and R21AI149161 awarded to OSA, and R01AI141532 awarded to GD. Our funders had no role in study design, data collection and analysis, decision to publish, or the preparation of this manuscript. Data Availability: All plasmids and annotated DNA sequence maps are available at www.addgene.com under accession numbers: #183993, #100581, #184006, #184007, #120363, #190997. Raw sequencing data are available at NCBI Sequence Read Archive, at https://www.ncbi.nlm.nih.gov/bioproject/PRJNA851480. Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: O.S.A. is a founder of both Agragene, Inc. and Synvect, Inc. with equity interest. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The authors report no other conflict of interest.

Attached Files

Published - ppat.1010842.pdf

Supplemental Material - ppat.1010842.s001.xlsx

Supplemental Material - ppat.1010842.s002.xlsx

Supplemental Material - ppat.1010842.s003.xlsx

Supplemental Material - ppat.1010842.s004.xlsx

Supplemental Material - ppat.1010842.s005.xlsx

Supplemental Material - ppat.1010842.s006.xlsx

Supplemental Material - ppat.1010842.s007.xlsx

Supplemental Material - ppat.1010842.s008.xlsx

Supplemental Material - ppat.1010842.s009.xlsx

Supplemental Material - ppat.1010842.s010.xlsx

Supplemental Material - ppat.1010842.s011.png

Supplemental Material - ppat.1010842.s012.png

Supplemental Material - ppat.1010842.s013.tiff

Supplemental Material - ppat.1010842.s014.docx

Supplemental Material - ppat.1010842.s015.pdf

Supplemental Material - ppat.1010842.s016.docx

Files

ppat.1010842.s011.png
Files (21.1 MB)
Name Size Download all
md5:b8bbad2bd500d4a4180ba3230f0db799
52.2 kB Preview Download
md5:6c623d82f420bf89360f468b4e4cca3c
51.5 kB Download
md5:55785b7f91cea7dfd705f3888ce147f8
5.6 MB Download
md5:e4a7801bea00d63f140cb59a7b59e32b
118.4 kB Preview Download
md5:4a7cfedc2c5204b43a6a35dc7bcde8dd
2.3 MB Download
md5:1b6ec32b9747e0b201938a2d9eaa249a
60.3 kB Download
md5:498c673054f33ac3fb909c49d8d124da
20.0 kB Download
md5:3fece261a121de3c1c5d5f5b5b598767
364.5 kB Download
md5:ed59fbd12ab1401889650b5ed6c293c2
2.3 MB Download
md5:351cf0d082558848e8f765148cb9e256
2.1 MB Preview Download
md5:5f2feef47972e1611f427ebba6ceb363
2.3 MB Download
md5:5fbdec6b07d0bd51d4885ee8723a12db
2.3 MB Preview Download
md5:da31aa2554408b56447b3feb8583c6d0
55.1 kB Download
md5:f0783f2ebbe8109e47cd988c53ba9735
51.3 kB Download
md5:93edb189174577f5004335dd35f0185c
12.9 kB Download
md5:7fc9a80dd9b0548cc076e87f7ee66656
991.5 kB Preview Download
md5:abe43155b0a0f9decfd8915c1c4d004c
2.3 MB Download

Additional details

Created:
August 22, 2023
Modified:
October 23, 2023